Ubs Asset Management Americas Inc Incyte Corp Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Incyte Corp stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,379,465 shares of INCY stock, worth $97.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,379,465

Previous 1,818,295 24.13%

Holding current value

$97.3 Million

Previous $110 Million 17.28%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $25.2 Million - $30.1 Million	-438,830 Reduced 24.13%	1,379,465 $91.2 Million
Q2 2024 Aug 13, 2024	BUY	$51.18 - $63.75 $31.3 Million - $39 Million	611,716 Added 50.7%	1,818,295 $110 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $632,398 - $744,675	-11,183 Reduced 0.92%	1,206,579 $68.7 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $15,230 - $18,743	-292 Reduced 0.02%	1,217,762 $76.5 Million
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $2.63 Million - $3 Million	45,528 Added 3.88%	1,218,054 $70.4 Million
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $23.6 Million - $28.9 Million	-335,758 Reduced 22.26%	1,172,526 $84.7 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $28.5 Million - $35.7 Million	-424,040 Reduced 21.94%	1,508,284 $121 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $15.9 Million - $19.9 Million	-240,557 Reduced 11.07%	1,932,324 $0
Q2 2022 Aug 12, 2022	SELL	$66.18 - $83.18 $8.68 Million - $10.9 Million	-131,115 Reduced 5.69%	2,172,881 $0
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $63.8 Million - $77 Million	966,254 Added 72.23%	2,303,996 $0
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $11.3 Million - $13.2 Million	-178,759 Reduced 11.79%	1,337,742 $0
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $2.06 Million - $2.52 Million	-29,959 Reduced 1.94%	1,516,501 $0
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $3 Million - $3.28 Million	37,528 Added 2.49%	1,546,460 $0
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $71.2 Million - $94.2 Million	-937,220 Reduced 38.31%	1,508,932 $0
Q4 2020 Mar 01, 2021	BUY	$80.74 - $97.7 $11 Million - $13.3 Million	136,492 Added 5.91%	2,446,152 $0
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $66.8 Million - $86.2 Million	-785,509 Reduced 25.38%	2,309,660 $0
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $40.7 Million - $59.7 Million	-548,292 Reduced 15.05%	3,095,169 $0
Q1 2020 May 15, 2020	BUY	$63.18 - $85.97 $25.7 Million - $34.9 Million	406,151 Added 12.55%	3,643,461 $0
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $31.7 Million - $41.6 Million	-434,490 Reduced 11.83%	3,237,310 $0
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $24.4 Million - $29 Million	-335,338 Reduced 8.37%	3,671,800 $0
Q2 2019 Aug 15, 2019	SELL	$73.52 - $88.7 $2.33 Million - $2.81 Million	-31,628 Reduced 0.78%	4,007,138 $0
Q1 2019 May 14, 2019	SELL	$63.56 - $88.17 $11.9 Million - $16.5 Million	-186,868 Reduced 4.42%	4,038,766 $0
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $43.5 Million - $52 Million	743,635 Added 21.36%	4,225,634 $0
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $5.02 Million - $6.03 Million	81,236 Added 2.39%	3,481,999 $0
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $157 Million - $217 Million	2,578,423 Added 313.55%	3,400,763 $0
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $7.13 Million - $8.67 Million	85,858 Added 11.66%	822,340 $0
Q4 2017 Feb 09, 2018	SELL	$93.56 - $116.6 $31 Million - $38.6 Million	-331,090 Reduced 31.01%	736,482 $0
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $117 Million - $148 Million	1,067,572	1,067,572 $0

Others Institutions Holding INCY

# of Institutions

642

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Incyte Corp Transaction History